Insmed Chief Argues For Five-Year Biologics Exclusivity
This article was originally published in The Pink Sheet Daily
Amgen was in the black on Neupogen/Neulasta three years after launch, CEO Allan contends.
You may also be interested in...
Despite regulatory murkiness, firm will forge ahead with new Phase III trial, CEO says.
Not enough understanding of debate, says Insmed exec; economic study to come
Governor Cuomo will establish two panels, one examining safety and efficacy and another considering distribution and pricing, to advise the state on how to approach use of coronavirus vaccines once one is approved.